当前位置： SCI文献检索 > NEUROCHEMISTRY INTERNATIONAL期刊下所有文献 > 2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects.

2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects.

Abstract：

:AMPA receptors are fast ligand-gated members of glutamate receptors in neuronal and many types of non-neuronal cells. The heterotetramer complexes are assembled from four subunits (GluR1-4) in region-, development- and function-selective patterns. Each subunit contains three extracellular domains (a large amino terminal domain, an agonist-binding domain and a transducer domain), and three transmembrane segments with a loop (pore forming domain), as well as the intracellular carboxy terminal tail (traffic and conductance regulatory domain). The binding of the agonist (excitatory amino acids and their derivatives) initiates conformational realignments, which transmit to the transducer domain and membrane spanning segments to gate the channel permeable to Na+, K+ and more or less to Ca2+. Several 2,3-benzodiazepines act as non-competitive antagonists of the AMPA receptor (termed also negative allosteric modulators), which are thought to bind to the transducer domains and inhibit channel gating. Analysing their effects in vitro, it has been possible to recognize a structure-activity relationship, and to describe the critical parts of the molecules involved in their action at AMPA receptors. Blockade of AMPA receptors can protect the brain from apoptotic and necrotic cell death by preventing neuronal excitotoxicity during pathophysiological activation of glutamatergic neurons. Animal experiments provided evidence for the potential usefulness of non-competitive AMPA antagonists in the treatment of human ischemic and neurodegenerative disorders including stroke, multiple sclerosis, Parkinson's disease, periventricular leukomalacia and motoneuron disease. 2,3-benzodiazepine AMPA antagonists can protect against seizures, decrease levodopa-induced dyskinesia in animal models of Parkinson's disease demonstrating their utility for the treatment of a variety of CNS disorders.

journal_name

Neurochem Int

journal_title

Neurochemistry international

authors

Szénási G,Vegh M,Szabo G,Kertesz S,Kapus G,Albert M,Greff Z,Ling I,Barkoczy J,Simig G,Spedding M,Harsing LG Jr

doi

10.1016/j.neuint.2007.07.002

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

166-83

issue

1-2

eissn

0197-0186

issn

1872-9754

pii

S0197-0186(07)00194-5

journal_volume

pub_type

杂志文章,评审

在线工具

2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects.